The maximum dose studied in clinical trials is 12 mg once weekly
"It covers the bone and is better than nothing, but it doesn't have the bounce and elasticity of natural cartilage, and it tends to degrade relatively quickly." The most recent research arose, in part, through the work of surgeon Matthew Murphy, PhD, a visiting researcher at Stanford who is now at the University of Manchester
A multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial (EudraCT 2007-0006731-31, NCT00777140) evaluated the safety, tolerability, and potential efficacy of DFO in patients with acute ischemic stroke in the middle cerebral artery region
Both documents came into force on January 1, 2026
Brains were cleared using iDISCO standard protocol 62,63
Your prescriber can discuss a personalised exit strategy when the time comes